Abstract

Nestle Health Science and Hutchison China MediTech (Chi-Med) have formed a 50-50 joint venture (JV) for the research, development, manufacturing and commercialisation of medicines and nutritional products derived from botanical extracts. The JV, to be named Nutrition Science Partners, will initially focus on gastrointestinal diseases and may subsequently expand into metabolic diseases and brain health. It will also assume responsibility for the development of Chi-Med’s HMPL-004, an oral therapy for inflammatory bowel disease that is derived from a botanical extract and which is scheduled to begin Phase III trials in early 2013.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.